ClinicalTrials.gg
CompletedNCT05986097Updated Oct 19, 2026Results posted

The Breakfast Study

An interventional study of Breakfast in Type 2 Diabetes, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan — 5 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Michigan.

Enrollment
9th of 36
119 · median 48
Started
2023
with 2 others
No phase
31 of 38
3 open now
Registered
32nd of 38
by date

Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, this one is the 9th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2023, is one of 31 with no phase, and was the 32nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, or all of them as a file.
02

Study summary

The investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators measured acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.

Read the detailed description

More than 15% of U.S. adults with type 2 diabetes have poorly controlled blood glucose, here defined as a glycated hemoglobin (HbA1c) level of 7.0% or higher. These adults have an elevated health risk of a variety of outcomes, including amputation and mortality from cardiovascular disease and from all causes. Nutrition- focused interventions can be effective for improving glycemic control, reducing anti-hyperglycemic medications, and reducing body weight, all of which are critical outcomes for adults with type 2 diabetes. However, typical nutrition-focused interventions can be burdensome, often requiring complex instructions and a complete overhaul of one's diet. Additionally, adults with poorly controlled type 2 diabetes are more likely to have low literacy levels, which can be a barrier for adherence to complex interventions. Therefore, an effective intervention for adults with poorly controlled diabetes who may have lower health literacy levels is necessary to reduce both HbA1c levels and anti-hyperglycemic medications. Carbohydrate intake has the strongest impact on post-prandial glycemia of any dietary factor, and a very low-carbohydrate diet-due to its ability to improve glycemic control-is now recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes. The investigators hypothesized that some of the benefits of a very low-carbohydrate diet may be available to individuals who change only their breakfasts to be very low-carbohydrate, rather than modifying their entire diet.

Thus, the investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, small- steps, low-literacy, very low-carbohydrate breakfast-focused program in 120 adults with poorly controlled type 2 diabetes. The investigators measured acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.

The investigators also tested whether factors such as sex, health literacy level, and baseline insulin resistance significantly moderate the impact of the intervention on change in HbA1c and change in anti-hyperglycemic medications.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Very low carbohydrate diet
  • Nutrition therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 7% or higher
  • 18-80 years old
  • The ability to understand verbal and written English
  • Willingness to follow the prescribed diet
  • Able to consent and follow directions
  • Willingness to regularly check blood glucose levels as required

Exclusion criteria

Exclusion Criteria:

  • Inability to provide
  • Pregnant, breastfeeding, or planning for either in the next 6 months or \<6 months postpartum
  • Low C-peptide and possible subsequent GAD 65 level that suggests type 1 diabetes, clinical factors that suggest type 1 diabetes (lean, lack of family history, and diabetic ketoacidosis in the past) or a previous diagnosis of type 1 diabetes or latent diabetes
  • Triglycerides are greater than 999mg/dL on the screening blood draw
  • Cancer, heart failure, or kidney failure
  • Vegan
  • Untreated mental health condition
  • Currently following a very low-carbohydrate diet or breakfasts
  • Thyroid levels out of range
  • Alcoholism
  • Previous bariatric surgery
  • Difficulty chewing or swallowing
  • Dependence on others for food preparation
  • Currently enrolled in another investigative study that might conflict with this research
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Very low-carbohydrate breakfast

    Materials encouraged eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.

    Behavioral: Breakfast

Interventions

  • BehavioralBreakfast

    Participants were provided recipes and information to support this dietary change.

06

What researchers measure

Primary outcomes

  1. Intervention Satisfaction

    A 1-item measure about intervention satisfaction. We asked participants, "How would you rate your overall satisfaction with the program?" The item was rated from 1 = very dissatisfied to 6 = very satisfied, with higher scores reflecting greater satisfaction.

    Time frame: At 4 months

  2. Assessment of Program Feasibility

    For feasibility, the percentage of completed sessions out of 16 possible sessions was calculated for each participant, and the mean percentage across participants was reported.

    Time frame: At Month 4

Secondary outcomes

  1. Weekly Dietary Adherence

    A 1-item measure about dietary adherence. We asked participants to reflect on the past week and rate whether they ate a low-carbohydrate breakfast. The item was rated from 1 = not at all to 7 = very much so, with higher scores reflecting greater adherence. Dietary adherence was collected weekly over the 4-month intervention. Average adherence across the intervention was reported.

    Time frame: Weekly over 4 months

  2. Change in PROMIS Sleep Disturbance T-score

    The 4-item PROMIS sleep disturbance subscale measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting more severe sleep problems. To assess the effect of dietary change on sleep disturbance, the change in PROMIS sleep disturbance T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  3. Change in PROMIS Pain Interference T-score

    The 4-item PROMIS subscale for pain interference measures the extent to which patients experience problems with pain interference over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater pain interference. To assess the effects of dietary changes on pain, the change in PROMIS pain interference T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  4. Change in PROMIS Anxiety T-score

    The 4-item PROMIS subscale for anxiety measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on anxiety, the change in PROMIS anxiety T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  5. Change in PROMIS Depression T-score

    The 4-item PROMIS subscale for depression measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on depression, the change in PROMIS depression T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  6. Change in PROMIS Fatigue T-score

    The 4-item PROMIS subscale for fatigue measures the extent to which patients experience problems with fatigue over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater fatigue. To assess the effects of dietary changes on fatigue, the change in PROMIS fatigue T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  7. Change in PROMIS Physical Function T-score

    The 4-item PROMIS subscale for physical function measures the extent to which patients experience problems with physical function over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better physical function. To assess the effects of dietary changes on physical function, the change in PROMIS physical function T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  8. Change in PROMIS Social Roles T-score

    The 4-item PROMIS subscale for social roles measures the extent to which patients experience problems with their social roles over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better social roles. To assess the effects of dietary changes on social roles, the change in PROMIS social roles T-scores from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  9. Change in PROMIS Pain Intensity

    The 1-item PROMIS subscale for pain intensity measures average pain intensity over the past 7 days using a 10-point Likert scale, with higher scores reflecting greater pain. To assess the effects of dietary changes on pain intensity, the change in PROMIS pain intensity score from baseline to 4 months was evaluated.

    Time frame: Baseline, 4 months

  10. Change in HbA1c

    HbA1c is the proportion of hemoglobin in the blood that has glucose attached to it relative to total hemoglobin. It reflects average blood glucose levels over approximately the previous 2-3 months. To assess the effect of dietary change on HbA1c, the change in HbA1c from baseline to 4 months were evaluated. A negative change indicates an improvement in HbA1c from baseline.

    Time frame: Baseline, 4 months

  11. Change in Anti-hyperglycemic Medications

    The Medication Effect Score (MES) quantifies the overall intensity of antiglycemic therapy based on potency and dosages of medications (Alexopoulos et al., 2021), with higher scores indicating greater medication intensity. It is interpreted as the reduction in HbA1c attributable to the medication regime. For each diabetes medication, the percentage of the maximum recommended daily dose is multiplied by an adjustment factor reflecting its expected hemoglobin A1c-lowering potency; these values are summed to yield the total MES. Scores range from 0 upward (no fixed maximum), with lower scores reflecting lower medication intensity. The change in MES from baseline to 4 months was evaluated, with negative values indicating a reduction in medication intensity.

    Time frame: Baseline, 4 months

07

Results

Posted Oct 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneVery Low-carbohydrate Breakfast
Started119
Completed115
Not completed4
Withdrew: Lost to follow-up3
Withdrew: Death1

Outcome measures

PrimaryIntervention Satisfaction

A 1-item measure about intervention satisfaction. We asked participants, "How would you rate your overall satisfaction with the program?" The item was rated from 1 = very dissatisfied to 6 = very satisfied, with higher scores reflecting greater satisfaction.

Time frame:
At 4 months
Reported as:
Mean · score on a scale
Intervention Satisfaction
score on a scaleVery Low-carbohydrate Breakfast
Intervention Satisfaction5.44 ± 0.91
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = <0.001 (A mean rating of 4.0 on the 0-6 scale was the a priori acceptability benchmark, with a meaningful difference of 5.0, one point above. A one-sample, two-tailed t-test compared the observed mean with 4.0.)
PrimaryAssessment of Program Feasibility

For feasibility, the percentage of completed sessions out of 16 possible sessions was calculated for each participant, and the mean percentage across participants was reported.

Time frame:
At Month 4
Reported as:
Mean · percentage of sessions completed
Assessment of Program Feasibility
percentage of sessions completedVery Low-carbohydrate Breakfast
Assessment of Program Feasibility90.20 ± 17.59
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = <0.001 (A 60% attendance rate was the a priori feasibility benchmark. A one-sample, two-tailed t-test compared mean attendance with 60%.)
SecondaryWeekly Dietary Adherence

A 1-item measure about dietary adherence. We asked participants to reflect on the past week and rate whether they ate a low-carbohydrate breakfast. The item was rated from 1 = not at all to 7 = very much so, with higher scores reflecting greater adherence. Dietary adherence was collected weekly over the 4-month intervention. Average adherence across the intervention was reported.

Time frame:
Weekly over 4 months
Reported as:
Mean · score on a scale
Weekly Dietary Adherence
score on a scaleVery Low-carbohydrate Breakfast
Weekly Dietary Adherence6.3 ± 1.1
SecondaryChange in PROMIS Sleep Disturbance T-score

The 4-item PROMIS sleep disturbance subscale measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting more severe sleep problems. To assess the effect of dietary change on sleep disturbance, the change in PROMIS sleep disturbance T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Sleep Disturbance T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Sleep Disturbance T-score-0.2 (-1.6 to 1.2)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.761 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Pain Interference T-score

The 4-item PROMIS subscale for pain interference measures the extent to which patients experience problems with pain interference over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater pain interference. To assess the effects of dietary changes on pain, the change in PROMIS pain interference T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Pain Interference T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Pain Interference T-score-0.0 (-1.4 to 1.3)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.967 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Anxiety T-score

The 4-item PROMIS subscale for anxiety measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on anxiety, the change in PROMIS anxiety T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Anxiety T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Anxiety T-score-0.7 (-2.0 to 0.6)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.290 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Depression T-score

The 4-item PROMIS subscale for depression measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on depression, the change in PROMIS depression T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Depression T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Depression T-score-0.9 (-2.0 to 0.2)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.115 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Fatigue T-score

The 4-item PROMIS subscale for fatigue measures the extent to which patients experience problems with fatigue over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater fatigue. To assess the effects of dietary changes on fatigue, the change in PROMIS fatigue T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Fatigue T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Fatigue T-score-0.8 (-2.2 to 0.6)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.240 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Physical Function T-score

The 4-item PROMIS subscale for physical function measures the extent to which patients experience problems with physical function over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better physical function. To assess the effects of dietary changes on physical function, the change in PROMIS physical function T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Physical Function T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Physical Function T-score-0.4 (-1.3 to 0.5)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.344 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Social Roles T-score

The 4-item PROMIS subscale for social roles measures the extent to which patients experience problems with their social roles over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better social roles. To assess the effects of dietary changes on social roles, the change in PROMIS social roles T-scores from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · T-score
Change in PROMIS Social Roles T-score
T-scoreVery Low-carbohydrate Breakfast
Change in PROMIS Social Roles T-score0.8 (-0.4 to 1.9)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.180 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in PROMIS Pain Intensity

The 1-item PROMIS subscale for pain intensity measures average pain intensity over the past 7 days using a 10-point Likert scale, with higher scores reflecting greater pain. To assess the effects of dietary changes on pain intensity, the change in PROMIS pain intensity score from baseline to 4 months was evaluated.

Time frame:
Baseline, 4 months
Reported as:
Mean · units on a scale
Change in PROMIS Pain Intensity
units on a scaleVery Low-carbohydrate Breakfast
Change in PROMIS Pain Intensity0.4 (0.0 to 0.8)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = 0.029 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in HbA1c

HbA1c is the proportion of hemoglobin in the blood that has glucose attached to it relative to total hemoglobin. It reflects average blood glucose levels over approximately the previous 2-3 months. To assess the effect of dietary change on HbA1c, the change in HbA1c from baseline to 4 months were evaluated. A negative change indicates an improvement in HbA1c from baseline.

Time frame:
Baseline, 4 months
Reported as:
Mean · % of hemoglobin with glucose (HbA1c)
Change in HbA1c
% of hemoglobin with glucose (HbA1c)Very Low-carbohydrate Breakfast
Change in HbA1c-0.4 (-0.6 to -0.2)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = <0.001 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)
SecondaryChange in Anti-hyperglycemic Medications

The Medication Effect Score (MES) quantifies the overall intensity of antiglycemic therapy based on potency and dosages of medications (Alexopoulos et al., 2021), with higher scores indicating greater medication intensity. It is interpreted as the reduction in HbA1c attributable to the medication regime. For each diabetes medication, the percentage of the maximum recommended daily dose is multiplied by an adjustment factor reflecting its expected hemoglobin A1c-lowering potency; these values are summed to yield the total MES. Scores range from 0 upward (no fixed maximum), with lower scores reflecting lower medication intensity. The change in MES from baseline to 4 months was evaluated, with negative values indicating a reduction in medication intensity.

Time frame:
Baseline, 4 months
Reported as:
Mean · MES units
Change in Anti-hyperglycemic Medications
MES unitsVery Low-carbohydrate Breakfast
Change in Anti-hyperglycemic Medications-0.2 (-0.4 to -0.1)
Statistical analysis
  • Very Low-carbohydrate Breakfast · t-test, 2 sided · p = <0.001 (We explored the change from baseline to the end of the study for this outcome, using a two-tailed paired t-test, with a significance level of 0.05 and 95% confidence intervals.)

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Very Low-carbohydrate Breakfast1/119 (0.8%)4/119 (3.4%)15/119 (12.6%)
Most frequent serious events
Most frequent serious events
EventVery Low-carbohydrate Breakfast
EncephalitisInfections and infestations1/119
Myocardial infarctionCardiac disorders1/119
Pericardial effusionCardiac disorders1/119
Colon cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/119
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/119
Most frequent other events
Most frequent other events
EventVery Low-carbohydrate Breakfast
HypoglycemiaMetabolism and nutrition disorders15/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)Very Low-carbohydrate Breakfast
Mean61.1 ± 11.1
Sex/Gender, Customized
Sex/Gender, Customized(participants)Very Low-carbohydrate Breakfast
Male44
Female73
Other2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Very Low-carbohydrate Breakfast
Hispanic or Latino9
Not Hispanic or Latino109
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Very Low-carbohydrate Breakfast
American Indian or Alaskan Native2
Asian4
Black or African American18
Native Hawaiian or other Pacific Islander0
White89
More than one race4
Other2
Region of Enrollment
Region of Enrollment(Participants)Very Low-carbohydrate Breakfast
United States119
PROMIS Sleep Disturbance T-score
PROMIS Sleep Disturbance T-score(T-score)Very Low-carbohydrate Breakfast
Mean50.5 ± 7.8
PROMIS Pain Interference T-score
PROMIS Pain Interference T-score(T-score)Very Low-carbohydrate Breakfast
Mean50.4 ± 8.8
PROMIS Anxiety T-score
PROMIS Anxiety T-score(T-score)Very Low-carbohydrate Breakfast
Mean50.3 ± 9.3

7 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
09

References and documents

Publications

  • Hansen A, Raymond K, Simon A, Kim S, Bayandorian H, Marriott D, Saslow LR. Very Low-Carbohydrate Breakfast Intervention for Adults with Type 2 Diabetes and Persistent Hyperglycemia: Protocol for a Digital, Nonrandomized Pre-Post Study. JMIR Res Protoc. 2026 Jan 28;15:e81041. doi: 10.2196/81041. PubMed 41605502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Oct 2025, 26 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 26 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Aug 14, 2023
StartActual
Aug 2, 2023
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 17, 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedIntervention satisfactionSatisfactionTime frame: At 4 months
  • AddedAssessment of Program FeasibilityTime frame: At Month 4
Oct 19, 2026
Documents
Secondary outcomes
2 edited, 3 description edited
What changed in the outcomes
  • EditedWeekly dietary adherenceDietary AdherenceTime frame: Weekly over 4 months
  • EditedChange in antiAnti-hyperglycemic medicationsMedicationsTime frame: Baseline, 4 months
  • DescriptionChange in PROMIS Anxiety T-score: how it is measured was reworded
  • DescriptionChange in PROMIS Pain Intensity: how it is measured was reworded
  • DescriptionChange in PROMIS Pain Interference T-score: how it is measured was reworded
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedIntervention satisfactionSatisfactionTime frame: At 4 months
    • AddedAssessment of Program FeasibilityTime frame: At Month 4
    Secondary outcomes 2 edited, 3 description edited
    What changed in the outcomes
    • EditedWeekly dietary adherenceDietary AdherenceTime frame: Weekly over 4 months
    • EditedChange in antiAnti-hyperglycemic medicationsMedicationsTime frame: Baseline, 4 months
    • DescriptionChange in PROMIS Anxiety T-score: how it is measured was reworded
    • DescriptionChange in PROMIS Pain Intensity: how it is measured was reworded
    • DescriptionChange in PROMIS Pain Interference T-score: how it is measured was reworded
    + 5 other changes: identifiers, verification date, responsible party, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05986097
Responsible party
Laura Saslow (Associate Professor, University of Michigan) — Principal investigator
First posted
Aug 14, 2023
Start date
Aug 2, 2023
Primary completion
Oct 9, 2025
Completion
Oct 17, 2025
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion